Sapphiros, a company creating consumer diagnostic technologies, was selected by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Tech program to develop a high-performance, over-the-counter, molecular multiplex respiratory diagnostic test that can rapidly detect RSV, influenza A, influenza B, and COVID in a single test.
Sapphiros has been awarded $11.1M to deliver the initial program of work, which combines proprietary isothermal molecular chemistries and proprietary high-volume, reel-to-reel conductive ink, printed electronics, and sensing technologies. These features are designed to deliver low-cost, easy-to-use, and rapidly deployable diagnostic tests. Upon successful completion of this initial program of work, Sapphiros will explore additional support and funding for the respiratory test, the company says.
“This is a significant milestone for our company and further validates Sapphiros’ unique and transformational technologies which, when combined, create one of the most innovative diagnostics products,” says Mark Gladwell, CEO of Sapphiros. “We are honored to play an important role in developing a platform that will have an immediate impact on improving patient outcomes and reducing healthcare costs, while enabling rapid response to future biosecurity threats and pandemics.”
This project has been funded, in part, with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services.
